UCB SA (OTCMKTS:UCBJY – Get Free Report) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $100.01 and last traded at $99.97, with a volume of 9355 shares traded. The stock had previously closed at $97.35.
UCB Stock Up 2.7 %
The firm’s fifty day moving average is $95.55 and its 200 day moving average is $87.64. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Recommended Stories
- Five stocks we like better than UCB
- How to Invest in the Best Canadian Stocks
- Dow Jones: A Relevant Benchmark or a Relic of the Past?
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 3 Big-Name Stocks Just Announced Big-Time Dividend Increases
- Stock Market Upgrades: What Are They?
- Market Overreaction: 2 Stocks to Buy on the Way Down
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
